Candel Therapeutics secures $130M loan to advance cancer therapy trials

Candel Therapeutics (NASDAQ:CADL) has secured a $130 million five-year term loan facility from Trinity Capital, with $50 million immediately drawn, significantly strengthening its balance sheet for late-stage development and potential commercialization of its cancer immunotherapies. This financing is crucial for initiating a pivotal Phase 3 clinical trial for CAN-2409 in non-small cell lung cancer by Q2 2026 and supporting its potential launch in early localized prostate cancer, with a Biologics License Application anticipated in late 2026. The loan, which carries an initial 10.25% annual interest rate, also enables the company to prioritize key programs and refinance existing debt, reflecting the lender's confidence in Candel's clinical data and substantial market potential.

Analysis

Candel Therapeutics (CADL) has secured a $130 million five-year term loan facility from Trinity Capital, with $50 million immediately drawn, significantly bolstering its balance sheet. This financing, combined with existing cash and equivalents of $87.2 million, provides substantial liquidity for critical development phases. The loan carries an initial annual interest rate of 10.25% with a 36-month interest-only period, indicating a structured approach to managing debt service while advancing clinical programs.

The capital infusion is earmarked for late-stage development and potential commercialization of cancer immunotherapies, specifically enabling the initiation of a pivotal Phase 3 clinical trial for CAN-2409 in non-small cell lung cancer (NSCLC) by Q2 2026. It also supports the potential launch of CAN-2409 in early localized prostate cancer, with a Biologics License Application (BLA) anticipated in late 2026. Trinity Capital's investment signals confidence in Candel's clinical data and the large commercial potential of these programs.

Candel will prioritize CAN-2409 development for prostate cancer and NSCLC, while seeking external partnerships for its pancreatic ductal adenocarcinoma program. The company will also advance its CAN-3110 program for recurrent glioblastoma, supported by positive interim Phase 1b data. This strategic allocation of resources, coupled with the refinancing of existing debt, positions Candel for key regulatory and commercial milestones, contributing to the strongly positive sentiment surrounding the announcement.

Key Decisions for Investors

• Monitor Candel Therapeutics' progress on the CAN-2409 Phase 3 trial initiation in NSCLC by Q2 2026 and the anticipated BLA for prostate cancer in late 2026, as these are critical value inflection points.
• Assess the company's ability to meet the regulatory, clinical, and operational milestones required to access the additional $50 million tranche, which will further de-risk its development pipeline.
• Consider the implications of the 10.25% interest rate on future profitability and cash flow, especially as the interest-only period concludes, while acknowledging the strategic value of the capital for advancing high-potential therapies.